Zacks Investment Research upgraded shares of Scpharmaceuticals (NASDAQ:SCPH) from a hold rating to a buy rating in a research report report published on Wednesday. The firm currently has $3.75 target price on the stock.
According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “
Separately, ValuEngine upgraded Scpharmaceuticals from a hold rating to a buy rating in a research note on Thursday, November 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Scpharmaceuticals currently has an average rating of Buy and a consensus target price of $10.44.
Shares of NASDAQ:SCPH opened at $3.90 on Wednesday. Scpharmaceuticals has a twelve month low of $3.37 and a twelve month high of $17.95. The company has a market cap of $73.53 million, a P/E ratio of -0.49 and a beta of 1.24. The company has a quick ratio of 13.03, a current ratio of 13.03 and a debt-to-equity ratio of 0.09.
Scpharmaceuticals (NASDAQ:SCPH) last announced its earnings results on Tuesday, November 13th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.22. On average, equities research analysts forecast that Scpharmaceuticals will post -1.75 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the business. AWM Investment Company Inc. raised its position in Scpharmaceuticals by 15.8% in the third quarter. AWM Investment Company Inc. now owns 469,799 shares of the company’s stock worth $2,758,000 after acquiring an additional 63,992 shares in the last quarter. JPMorgan Chase & Co. raised its position in Scpharmaceuticals by 1,268.6% in the third quarter. JPMorgan Chase & Co. now owns 22,664 shares of the company’s stock worth $133,000 after acquiring an additional 21,008 shares in the last quarter. Northern Trust Corp raised its position in Scpharmaceuticals by 41.6% in the second quarter. Northern Trust Corp now owns 67,932 shares of the company’s stock worth $384,000 after acquiring an additional 19,947 shares in the last quarter. Colony Group LLC purchased a new position in Scpharmaceuticals in the second quarter worth $131,000. Finally, BlackRock Inc. raised its position in Scpharmaceuticals by 20.7% in the second quarter. BlackRock Inc. now owns 348,086 shares of the company’s stock worth $1,970,000 after acquiring an additional 59,617 shares in the last quarter. 43.40% of the stock is owned by hedge funds and other institutional investors.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Read More: Consumer behavior in bull markets
Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.